Tony works with the senior management team at Cobra Biologics, part of Charles Rivers Laboratories, developing service offerings through internal development and investment, collaborative projects and long term strategic investments. Tony’s focus is also on developing relationships with academic, NGO and industrial partners such as the National Horizons Centre. Tony brings over 35 years’ industry experience to the Board helping to inform skills development to establish long term manufacturing capabilities in the biopharma sectors.
The Biotechnology and Biological Sciences Research Council (BBSRC) is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government. BBSRC invests in world-class bioscience research and training on behalf of the UK public. As Head of Business Engagement & Intelligence in the Business Interaction Unit, Ruth delivers industrially relevant collaborative R&D programmes with the bioscience research base.
Chris leads the process development, scale-up and process validation across a range of Biologic APIs for client projects with a focus on Gene Therapies. With over 10 years’ industry experience Chris has been the Drug Substance lead for late-stage assets, has overseen agency submissions across multiple regions, and gained first-hand experience of FDA pre-approval inspections. He also has experience developing Pharmaron’s learning academy at their Liverpool site, as well as advising universities on their life sciences curriculums.
As Senior Director R&D (Vaccines MS&T) at AstraZeneca, Gareth has a proven track record of strong leadership, developing and executing medium and long term site wide strategies in a complex fast moving environment. His role includes vaccines development and manufacturing technical strategy, virology research and seasonal strain development.
A champion of developing the next generation of talent, Gareth provides an important connection to industry, ensuring the NHC’s training is relevant to challenges we face today and envisage for tomorrow.
One of the founding directors of Lakes BioScience, Pat has more than 30 years’ pharma industry experience including leadership roles in commercial, logistics, aseptic manufacturing, business systems, communications, and strategic programme management. A proud advocate of the local community and talent, Pat previously headed GSK’s plans in Ulverston for a flagship UK biopharmaceutical facility. Pat maintains strong relationships with partners and stakeholder organisations to drive forward Lakes BioScience vision to establish large scale contract development and manufacturing operations in Cumbria, establishing the UK as a leading player in the global biopharmaceutical manufacturing market.
As Head of Science at FUJIFILM Diosynth Biotechnologies UK, Ray support the development of manufacturing processes for biotherapeutics. This highly technical role relies on his 30 years of experience gained within the biotechnology/pharmaceutical sector. Ray is involved in setting up and running partnership innovation projects with academic institutions.
Brendan and his team have technical accountability for the introduction of all new products to GSK Barnard Castle as well as managing the technical support of existing products. This includes all aspects of process validation, commercial manufacture, filling, inspection and packaging for sterile liquids (including biologics), inhaled liquids, creams and ointments.
Brendan brings significant experience to the Board in the development of biotechnology-based products providing expert opinion and strategies for QA, QC, production, marketing, operations, Regulatory Affairs and engineering on all aspects of process development and validation, scale-up and launch.
Gary Finka has over 25 years of experience within the Biopharmaceutical industry. Sitting at the interface of Discovery and CMC his responsibilities cover the generation and selection of commercial CHO-based cell lines and the application of developability approaches to de-risk the progression of the GSK biopharmaceutical portfolio to late-stage development and manufacturing. Key areas of interest are process scale-down, high-throughput bioprocessing, Process Analytical Technologies (PAT) and Informatics/process modelling.